The US Food and Drug Administration has approved talazoparib with enzalutamide for an earlier treatment setting in a genetically defined group of adults with metastatic prostate cancer.
The decision, announced on Monday, 26 October, covers cancers with homologous recombination repair (HRR) gene mutations identified by an FDA-authorised test. It applies to metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, not every prostate-cancer diagnosis.
Pfizer, which markets talazoparib as Talzenna, describes this setting as metastatic hormone-sensitive prostate cancer: disease that has spread beyond the prostate but remains sensitive to hormone treatment. The company said the combination had previously received US approval in 2023 for a later, treatment-resistant setting.
Trial shows a delay in progression
The FDA based its decision on TALAPRO-3, a randomised trial involving 599 patients. Researchers compared enzalutamide plus talazoparib with enzalutamide plus a placebo; both groups also received androgen deprivation therapy.
The regulator reported a statistically significant improvement in the time before scan-confirmed disease progression or death. Overall-survival data were still immature, so the findings should not be presented as proof that the combination extends life.
Risks remain important. The FDA lists warnings for bone-marrow suppression and serious blood disorders, including myelodysplastic syndrome and acute myeloid leukaemia. Pfizer reported severe anaemia in 51% of patients receiving the combination in TALAPRO-3, compared with 3% in the control group.
US approval is not a South African access announcement
A SAHPRA-hosted Talzenna product document approved in December 2024 describes a breast-cancer indication. That older document does not establish whether this new prostate-cancer use is currently authorised in South Africa.
South African approval for the newly announced indication, local availability and funding have not been verified. Monday’s announcement concerns the US regulatory decision, not a South African treatment rollout.
